Publications

  1. Antwi SO, Eckel-Passow JE, Diehl ND, Serie DJ, Custer KM, Arnold ML, Wu KJ, Cheville JC, Thiel DD, Leibovich BC, Parker AS. Coffee consumption and risk of renal cell carcinoma. Cancer Causes Control 2017 Aug; 28 (8):857-866 Epub 2017 June 24
    View PubMed
  2. Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Buskirk SJ. GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol 2017 Jul; 90 (1075):20170174 Epub 2017 June 16
    View PubMed
  3. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun 2017 Jun 09; 8:15724 Epub 2017 June 09
    View PubMed
  4. Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. Eur Urol 2017 Jun; 71 (6):979-985 Epub 2016 Nov 26
    View PubMed
  5. Pathak RA, Thiel DD, Parker A, Heckman MG, Crook JE, Diehl NN, Tavlarides A, Alford SW, Igel TC. Timing interval from peri-prostatic block to biopsy impacts procedural pain. Can J Urol 2017 Jun; 24 (3):8795-8801
    View PubMed
  6. Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urol 2017 Mar 21; 17 (1):19
    View PubMed
  7. Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, Parker AS, Eckel-Passow JE. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncol 2017 Mar 01; 28 (3):604-610
    View PubMed
  8. Parasramka M, Serie DJ, Asmann YW, Eckel-Passow JE, Castle EP, Stanton ML, Leibovich BC, Thompson RH, Thompson EA, Parker AS, Ho TH, Joseph RW. Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. Eur Urol Focus 2016 Dec 15; 2 (6):608-615 Epub 2016 Apr 02
    View PubMed
  9. Cernigliaro JG, Haley WE, Adolphson DP, Jepperson MA, Crook JE, Thomas CS, Parker AS. Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol. Clin Imaging 2016 Sep-Oct; 40 (5):902-6 Epub 2016 Apr 26
    View PubMed
  10. Merten JW, Parker A, Williams A, King JL, Largo-Wight E, Osmani M. Cancer Risk Factor Knowledge Among Young Adults. J Cancer Educ 2016 Aug 6 Epub 2016 Aug 06
    View PubMed
  11. Clendenen N, Cannon AD, Porter S, Robards CB, Parker AS, Clendenen SR. Whole-exome sequencing of a family with local anesthetic resistance. Minerva Anestesiol 2016 May 31 [Epub ahead of print]
    View PubMed
  12. Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene 2016 Mar 24; 35 (12):1565-74 Epub 2015 June 15
    View PubMed
  13. Thiel DD, Davidiuk AJ, Meschia C, Serie D, Custer K, Petrou SP, Parker AS. Mayo Adhesive Probability Score Is Associated With Localized Renal Cell Carcinoma Progression-free Survival. Urology 2016 Mar; 89:54-60 Epub 2015 Dec 23
    View PubMed
  14. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. J Urol 2016 Jan; 195 (1):180-7 Epub 2015 Aug 20
    View PubMed
  15. Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol 2016 Jan; 29 (1):34-42 Epub 2015 Oct 30
    View PubMed
  16. Tyson MD 2nd, Andrews PE, Ferrigni RF, Humphreys MR, Parker AS, Castle EP. Radical Prostatectomy Trends in the United States: 1998 to 2011. Mayo Clin Proc 2016 Jan; 91 (1):10-6
    View PubMed
  17. Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ. An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. PLoS One 2016; 11 (3):e0151785 Epub 2016 Mar 17
    View PubMed
  18. Wu L, Chaffee KG, Parker AS, Sicotte H, Petersen GM. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer. Tumour Biol 2015 Sep; 36 (10):7431-7 Epub 2015 Apr 23
    View PubMed
  19. Tavlarides AM, Ames SC, Thiel DD, Diehl NN, Parker AS. Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer. Psychooncology 2015 Apr; 24 (4):451-7 Epub 2014 June 21
    View PubMed
  20. Davidiuk AJ, Parker AS, Thomas CS, Heckman MG, Custer K, Thiel DD. Prospective evaluation of the association of adherent perinephric fat with perioperative outcomes of robotic-assisted partial nephrectomy. Urology. 2015 Apr; 85(4):836-42. Epub 2015 Feb 07.
    View PubMed
  21. Tacik P, Guthrie KJ, Strongosky AJ, Broderick DF, Riegert-Johnson DL, Tang S, El-Khechen D, Parker AS, Ross OA, Wszolek ZK. Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. Mayo Clin Proc 2015 Mar; 90 (3):366-71 Epub 2015 Feb 03
    View PubMed
  22. Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors 2015 Feb 11; 7 (1):5719 Epub 2015 Feb 25
    View PubMed
  23. Eckel-Passow JE, Igel DA, Serie DJ, Joseph RW, Ho TH, Cheville JC, Parker AS. Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis. Urol Oncol 2015 Feb; 33 (2):68.e17-23 Epub 2014 Aug 28
    View PubMed
  24. Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol 2015 Jan; 33 (1):23.e9-23.e14 Epub 2014 Nov 24
    View PubMed
  25. Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors. 2015; 7(1):29-33.
  26. Thiel DD, Davidiuk AJ, Broderick GA, Arnold M, Diehl N, Tavlarides A, Custer K, Parker AS. Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma. BMC Urol 2015; 15:58 Epub 2015 July 01
    View PubMed
  27. Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP. A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS One 2015; 10 (7):e0132831 Epub 2015 July 16
    View PubMed
  28. Davidiuk AJ, Parker AS, Thomas CS, Leibovich BC, Castle EP, Heckman MG, Custer K, Thiel DD. Mayo adhesive probability score: an accurate image-based scoring system to predict adherent perinephric fat in partial nephrectomy. Eur Urol 2014 Dec; 66 (6):1165-71 Epub 2014 Sept 02
    View PubMed
  29. Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Eur Urol 2014 Nov; 66 (5):929-35 Epub 2013 Dec 25
    View PubMed
  30. Jorns J, Thiel DD, Arnold ML, Diehl N, Cernigliaro JC, Wu KJ, Parker AS. Correlation of radiographic renal cell carcinoma tumor volume utilizing computed tomography and magnetic resonance imaging compared with pathological tumor volume. Scand J Urol. 2014 Oct; 48(5):453-9. Epub 2014 Jul 03.
    View PubMed
  31. Chen LM, Chang M, Dai Y, Chai KX, Dyrskjot L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev 2014 Sep; 23 (9):1804-12 Epub 2014 June 11
    View PubMed
  32. Parker AS, Arnold ML, Diehl ND, Hassan L, Thiel DD. Evaluation of awareness of risk factors for kidney cancer among patients presenting to a urology clinic. Scand J Urol. 2014 Jun; 48(3):239-44. Epub 2013 Dec 12.
    View PubMed
  33. Hutchinson R, Parker AS, Arnold M, Bowers SP, Haley WE, Diehl N, Stone R, Lynch SA, Smith CD, Thiel DD. Prospective evaluation of 24-hour urine profiles following bariatric surgery in a modern comprehensive care bariatric clinic. Clin Nephrol. 2014 May; 81(5):331-7.
    View PubMed
  34. Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Hart SN, Cheville JC, Parker AS. Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. Carcinogenesis 2014 Apr; 35 (4):822-7 Epub 2013 Dec 28
    View PubMed
  35. Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014 Apr 01; 120 (7):1059-67 Epub 2013 Dec 30
    View PubMed
  36. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10.
    View PubMed
  37. Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC, Parker AS. ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. BMC Urol 2014 Jan 31; 14:14
    View PubMed
  38. Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, Parker AS, Drake RR. MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics. 2014; 14(7-8):924-35.
    View PubMed
  39. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One 2014; 9 (6):e96705 Epub 2014 June 04
    View PubMed
  40. Thiel DD, Jorns J, Lohse CM, Cheville JC, Thompson RH, Parker AS. Maximum tumor diameter is not an accurate predictor of renal cell carcinoma tumor volume. Scand J Urol. 2013 Dec; 47(6):472-5. Epub 2013 Jul 24.
    View PubMed
  41. Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, Diehl N, Karnes RJ. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):352-6. Epub 2013 Aug 20.
    View PubMed
  42. Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A. Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol Res 2013 Dec; 1 (6):378-85 Epub 2013 Aug 29
    View PubMed
  43. Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ. Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer. J Radiat Oncol 2013 Sep 01; 2 (3):309-314
    View PubMed
  44. Tyson MD, Humphreys MR, Parker AS, Thiel DD, Joseph RW, Andrews PE, Castle EP. Age-period-cohort analysis of renal cell carcinoma in United States adults. Urology. 2013 Jul; 82(1):43-7. Epub 2013 May 22.
    View PubMed
  45. Tyson MD, Humphreys MR, Castle EP, Parker AS. Reply. Urology. 2013 Jul; 82(1):47. Epub 2013 May 22.
    View PubMed
  46. Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, Broderick GA, Parker AS. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology. 2013 Jun; 22(6):1328-35. Epub 2012 Aug 01.
    View PubMed
  47. McLaughlin SA, Bagaria S, Gibson T, Arnold M, Diehl N, Crook J, Parker A, Nguyen J. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2013 Mar; 216(3):380-9; quiz 511-3. Epub 2012 Dec 21.
    View PubMed
  48. Joseph RW, Serie D, Hilton TW, Parasramka M, Eckel-Passow J, Cheville J, Leibovich BC, Parker AS. Association of topoisomerase II expression and cancer-specific death in patients with surgically resected clear cell renal cell carcinoma. J Clin Oncol 2013 Feb 20; 31 (6_suppl):446
    View PubMed
  49. Mmeje CO, Martin AD, Nunez-Nateras R, Parker AS, Thiel DD, Castle EP. Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. Curr Urol Rep. 2013 Feb; 14(1):26-31.
    View PubMed
  50. McDonnell SK, Riska SM, Klee EW, Thorland EC, Kay NE, Thibodeau SN, Parker AS, Eckel-Passow JE. Experimental designs for array comparative genomic hybridization technology. Cytogenet Genome Res 2013; 139 (4):250-7 Epub 2013 Mar 27
    View PubMed
  51. Peterson JL, Buskirk SJ, Heckman MG, Parker AS, Diehl NN, Tzou KS, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Pisansky TM. Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer. ISRN Oncol 2013; 2013:239241 Epub 2013 Mar 31
    View PubMed
  52. Arnold ML, Thiel DD, Diehl N, Wu KJ, Ames S, Parker AS. Comparison of baseline quality of life measures between renal cell carcinoma patients undergoing partial versus radical nephrectomy. BMC Urol. 2013; 13:52. Epub 2013 Oct 22.
    View PubMed
  53. Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate 2012 Dec 01; 72 (16):1757-66 Epub 2012 Apr 18
    View PubMed
  54. Petrou SP, Rogers AE, Parker AS, Green KM, McRoberts JW. Dorsal vaginal graft urethroplasty for female urethral stricture disease. BJU Int. 2012 Dec; 110(11 Pt C):E1090-5. Epub 2012 May 17.
    View PubMed
  55. Jepperson MA, Thiel DD, Cernigliaro JG, Broderick GA, Parker AS, Haley WE. Determination of ureter stent appearance on dual-energy computed tomography scan. Urology 2012 Nov; 80 (5):986-9 Epub 2012 Aug 22
    View PubMed
  56. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother 2012 Nov-Dec; 35 (9):711-5
    View PubMed
  57. Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int. 2012 Oct; 110(7):956-60. Epub 2012 Feb 02.
    View PubMed
  58. Thiel DD, Lohse CM, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus? Int Urol Nephrol. 2012 Aug; 44(4):1005-12. Epub 2012 Apr 13.
    View PubMed
  59. Hutchinson RC, Thiel DD, Tavlarides AM, Diehl NN, Parker AS. The effect of robot-assisted laparoscopic prostatectomy on nocturia. J Endourol 2012 Jul; 26 (7):861-5 Epub 2012 Apr 17
    View PubMed
  60. Jorns JJ, Thiel DD, Lohse C, Williams A, Arnold M, Cheville J, Leibovich B, Parker AS. Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinoma. Urology. 2012 Jul; 80(1):147-50.
    View PubMed
  61. Bot BM, Eckel-Passow JE, LeGrand SN, Hilton T, Cheville JC, Igel T, Parker AS. Expression of endothelin 2 and localized clear cell renal cell carcinoma. Hum Pathol 2012 Jun; 43 (6):843-9 Epub 2011 Nov 01
    View PubMed
  62. Adkisson CD, Bagaria SP, Parker AS, Bray JM, Gibson T, Thomas CS, Heckman MG, McLaughlin SA. Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer? Ann Surg Oncol 2012 Apr; 19 (4):1129-36
    View PubMed
  63. Thiel DD, Hutchinson R, Diehl N, Tavlarides A, Williams A, Parker AS. Impact of fellowship training on one-year outcomes of robotic-assisted prostatectomy. JSLS 2012 Apr-Jun; 16 (2):195-201
    View PubMed
  64. Thiel DD, Brisson TE, Heckman MG, Arnold M, Haley W, Khambhati J, Wehle MJ, Igel TC, Parker AS. Evaluation of pancreatic damage after extracorporeal shock wave lithotripsy, percutaneous stone surgery, and ureteroscopy. Urology. 2011 Jun; 77(6):1288-91. Epub 2011 Jan 07.
    View PubMed
  65. McLaughlin SA, Bagaria SP, Nguyen JH, Arnold M, Diehl NN, Gibson T, Crook J, Parker AS. Exploration of patient anxiety 1 year after surgery for breast cancer. J Clin Oncol 2011 May 20; 29 (15_suppl):e19590
    View PubMed
  66. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  67. Jacobson DJ, St Sauver JL, Parker AS, McGree ME, Sarma AV, Girman CJ, Lieber MM, Jacobsen SJ. Estimation of prostate size in community-dwelling men. Urology 2011 Feb; 77 (2):422-6 Epub 2010 Aug 30
    View PubMed
  68. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011; 29(6):593-605.
    View PubMed
  69. Thiel DD, Brisson TE, Heckman MG, Arnold M, Haley WE, Khambhati J, Wehle MJ, Igel TC, Parker AS. Evaluation of pancreatic damage after extracorporeal shock wave lithotripsy, percutaneous stone surgery, and ureteroscopy. J Endourol. 2011; 25(11):1690-1.
  70. Leroy TJ, Thiel DD, Duchene DA, Parker AS, Igel TC, Wehle MJ, Goetzl M, Thrasher JB. Safety and peri-operative outcomes during learning curve of robot-assisted laparoscopic prostatectomy: a multi-institutional study of fellowship-trained robotic surgeons versus experienced open radical prostatectomy surgeons incorporating robot-assisted laparoscopic prostatectomy. J Endourol 2010 Oct; 24 (10):1665-9
    View PubMed
  71. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Dec 1; 75(5):1364-70. Epub 2009 May 21.
    View PubMed
  72. Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc. 2009 Aug; 84(8):702-6.
    View PubMed
  73. Feldstein MS, Rhodes DJ, Parker AS, Orford RR, Castle EP. The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int. 2009 Jul; 104(1):53-6. Epub 2009 Jan 12.
    View PubMed
  74. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009 May 15; 115 (10):2092-103
    View PubMed
  75. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):444-53. Epub 2009 Feb 03.
    View PubMed
  76. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol 2008 Aug; 39 (8):1176-84 Epub 2008 June 05
    View PubMed
  77. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA, Anastasiadis PZ. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem 2008 Jun 27; 283 (26):18344-54 Epub 2008 Apr 11
    View PubMed
  78. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008 Apr 1; 112 (7):1471-9
    View PubMed
  79. Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol. 2008 Apr; 15(4):304-8.
    View PubMed
  80. Parker AS, Lewis R, Heckman MG, Diehl NH, Brisson T, Pak R, Wehle MJ. Evaluation of the impact of body mass index on outcome among renal mass patients treated with hand-assisted laparoscopic radical nephrectomy. J Endourol 2008 Feb; 22 (2):301-6
    View PubMed
  81. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenheim JL, Gile GG, Giovannucci E, Horn-Ross PL, Leitzmann M, Marshall JR, Mannisto S, McCullough ML, Miller AB, Parker AS, Pietinen P, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer. 2007 Nov 15; 121(10):2246-53.
    View PubMed
  82. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007 Aug 15; 13 (16):4740-9
    View PubMed
  83. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, Folsom AR, Freudenheim JL, Giovannucci E, Graham S, Horn-Ross PL, Leitzmann MF, McCullough ML, Miller AB, Parker AS, Rodriguez C, Rohan TE, Schatzkin A, Schouten LJ, Virtanen M, Willett WC, Wolk A, Zhang SM, Smith-Warner SA. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007 May 16; 99(10):801-10.
    View PubMed
  84. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1749-56.
    View PubMed
  85. Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol 2007 Mar; 38 (3):453-61 Epub 2006 Dec 22
    View PubMed
  86. Tarpey P, Thomas S, Sarvananthan N, Mallya U, Lisgo S, Talbot CJ, Roberts EO, Awan M, Surendran M, McLean RJ, Reinecke RD, Langmann A, Lindner S, Koch M, Jain S, Woodruff G, Gale RP, Degg C, Droutsas K, Asproudis I, Zubcov AA, Pieh C, Veal CD, Machado RD, Backhouse OC, Baumber L, Constantinescu CS, Brodsky MC, Hunter DG, Hertle RW, Read RJ, Edkins S, O'Meara S, Parker A, Stevens C, Teague J, Wooster R, Futreal PA, Trembath RC, Stratton MR, Raymond FL, Gottlob I. Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. Nat Genet. 2006 Nov; 38(11):1242-4. Epub 2006 Oct 01.
    View PubMed
  87. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006 Oct; 68(4):741-6.
    View PubMed
  88. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006 Sep; 176 (3):985-90
    View PubMed
  89. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 1; 107(1):37-45.
    View PubMed
  90. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66(7):3381-5.
    View PubMed
  91. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005 Jul 15; 11(14):5128-39.
    View PubMed
  92. Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology 2005 Jun; 65 (6):1090-5
    View PubMed
  93. Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer. 2004 Jun 15; 100(12):2577-82.
    View PubMed
  94. Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol. 2004 Jan 1; 159(1):42-8.
    View PubMed
  95. Parker AS, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol. 2003 Aug; 170(2 Part 1):420-4.
    View PubMed
  96. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer. 2003 Apr 1; 97(7):1663-71.
    View PubMed
  97. Parker AS, Cerhan JR, Janney CA, Lynch CF, Cantor KP. Smoking cessation and renal cell carcinoma. Ann Epidemiol. 2003 Apr; 13(4):245-51.
    View PubMed
  98. Yang P, Cerhan JR, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Parker AS, Anderson KE, Sellers TA. Adenocarcinoma of the lung is strongly associated with cigarette smoking: Further evidence from a prospective study of women. Am J Epidemiol. 2002 Dec 15; 156(12):1114-22.
    View PubMed
  99. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol. 2002 Aug; 33(8):801-5.
    View PubMed
  100. Parker AS, Cerhan JR, Lynch CF, Ershow AG, Cantor KR. Gender, alcohol consumption, and renal cell carcinoma. Am J Epidemiol. 2002 Mar 1; 155(5):455-62.
    View PubMed
  101. Cerhan JR, Wallace RB, Dick F, Kemp J, Parker AS, Zheng W, Sellers TA, Folsom AR. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):361-8.
    View PubMed
  102. Cerhan JR, Putnam SD, Bianchi GD, Parker AS, Lynch CF, Cantor KP. Tea consumption and risk of cancer of the colon and rectum. Nutr Cancer. 2001; 41(1-2):33-40.
    View PubMed
  103. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000 Aug; 10(6):361-9.
    View PubMed
  104. Parker AS, Cerhan JR, Dick F, Kemp J, Habermann TM, Wallace RB, Sellers TA, Folsom AR. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women. Leuk Lymphoma. 2000 Apr; 37(3-4):341-9.
    View PubMed
  105. Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP. Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol. 2000 Feb 15; 151(4):377-83.
    View PubMed
  106. Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. Epidemiology. 1999 Jul; 10(4):452-5.
    View PubMed
  107. Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, Torner JC, Cantor KP. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev. 1999 Jan; 8(1):53-60.
    View PubMed
  108. Clemmons DR, Busby W Jr, Clarke JB, Parker A, Duan C, Nam TJ. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions Endocrine Journal. 1998; 45(Suppl):S1-8.
    View PubMed
  109. Parker A, Rees C, Clarke J, Busby WH Jr, Clemmons DR. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I Molecular Biology of the Cell. 1998; 9(9):2383-92.
    View PubMed
  110. Arai T, Clarke J, Parker A, Busby W Jr, Nam T, Clemmons DR. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin Journal of Biological Chemistry. 1996; 271(11):6099-106.
    View PubMed
  111. Parker A, Clarke JB, Busby WH Jr, Clemmons DR. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5 Journal of Biological Chemistry. 1996; 271(23):13523-9.
    View PubMed
  112. Parker A, Gockerman A, Busby WH, Clemmons DR. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells Endocrinology. 1995; 136(6):2470-6.
    View PubMed
  113. Gross CR, Savik SK, Ascher NL, Gordon RD, Klintmalm GB, Payne W, Shaw BW, Strasburg K, Parker A, Wiesner RH. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients. Transplant Proc. 1994 Oct; 26(5):2686-90.
    View PubMed
  114. Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes Journal of Biological Chemistry. 1994; 269(32):20388-93.
    View PubMed